ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Bristol-Myers, Calibr In Fibrosis Pact

by Lisa M. Jarvis
January 12, 2015 | APPEARED IN VOLUME 93, ISSUE 2

[+]Enlarge
Credit: Lisa Jarvis/C&EN
Scientists in Calibr’s high-throughput screening facility.
09302-buscon-calibrcxd.jpg
Credit: Lisa Jarvis/C&EN
Scientists in Calibr’s high-throughput screening facility.

To further expand its portfolio of antifibrotic drugs, Bristol-Myers Squibb has teamed with California Institute for Biomedical Research (Calibr) to develop small molecules that can stop or slow the progression of fibrotic disease. BMS gains the rights to any preclinical antifibrotic compounds discovered by Calibr, a La Jolla-based nonprofit focused on translational science.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment